HGS and Kirin in new antibody treatment

Published: 1-Jan-2003
Sustainability


US company Human Genome Sciences has signed a licence agreement with the pharmaceutical division of Kirin Brewery Company, of Japan, under which the two companies will collaborate on the development and commercialisation of agonistic human monoclonal antibodies to TRAIL Receptor-2. The TRAIL (tumor necrosis factor apoptosis-inducing ligand) Receptor-1 and TRAIL Receptor-2 proteins were discovered by Human Genome Sciences.

Under the terms of the agreement, Human Genome Sciences and Kirin will work together to identify and optimise the best candidate to enter into clinical development. Development and commercialisation of any resulting drug will be undertaken by Kirin in Japan and Asia/Australasia, and by Human Genome Sciences in North America, Europe and the rest of the world.

Dr William A. Haseltine, chairman and ceo of Human Genome Sciences, said, "We are pleased that we will be working with Kirin to develop and commercialise an agonistic human monoclonal antibody to TRAIL Receptor-2 in Japan and Asia/Australasia.

'We are also pleased that we will now have the opportunity to study the Kirin antibodies to TRAIL Receptor-2, alongside our own, to determine the optimal drug candidate to enter into clinical trials and, hopefully, to develop and commercialise worldwide. We look forward to completing the preclinical development of TRAIL-R2 mAb, and to entering this promising antitumour drug candidate into clinical trials.'

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
  3. Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
  4. Five API manufacturing trends you need to know in 2025 How technology, sustainability and innovation are redefining pharmaceutical production
  5. GEA raises guidance following strong H1 performance Revised forecast reflects improved margins, robust order intake and efficiency gains

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Manufacturing

Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS

The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Sustainability

Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress

This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
Sustainability

Piramal Pharma publishes FY2025 sustainability report, outlining performance and decarbonization glidepath

Piramal Pharma Limited has released its fourth annual Sustainability Report for the financial year 2025, under the theme ‘Innovating Responsibly. Growing Sustainably.’
Sustainability

LOCTITE to showcase next generation of healthcare adhesive innovations

New biocompatible adhesives aim to improve safety, performance, and sustainability
Sustainability

IMCD receives upgraded ESG ratings from ISS ESG and Sustainalytics

Improvements reflect continued progress on emissions, transparency and ESG risk management
Subscribe now